S. 932 · 119th Congress

Give Kids a Chance Act of 2025

Introduced on Mar 11, 2025 by Markwayne Mullin (R-OK). 20 cosponsors, 10 of them from another party. Latest action (Mar 11, 2025): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Stage
Introduced
Introduced
Mar 11, 2025
Cosponsors
20
10 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Markwayne MullinR-OKSponsor

Democrats · 10

Republicans · 10

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Mar 11, 2025Introduced in Senate
  2. Mar 11, 2025 · SenateRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. IONIS PHARMACEUTICALS, INC.11 reports
    $760K reported (all issues)
  2. BIOTECHNOLOGY INNOVATION ORGANIZATION10 reports
    $3.1M reported (all issues)
  3. PTC THERAPEUTICS, INC.10 reports
    $1M reported (all issues)
  4. STEALTH BIOTHERAPEUTICS INC.10 reports
    $620K reported (all issues)
  5. ACADIA PHARMACEUTICALS9 reports
    $3.1M reported (all issues)
  6. ALLIANCE FOR REGENERATIVE MEDICINE9 reports
    $790K reported (all issues)
  7. Travere Therapeutics9 reports
    $1.1M reported (all issues)Federal contractor: TRAVERE THERAPEUTICS, INC.$323.9K in contracts, FY2026AI match · 100%
  8. HealthCare Institute of New Jersey7 reports
    $333.2K reported (all issues)
  9. Biotechnology Innovation Organization (BIO)6 reports
    $360K reported (all issues)
  10. CURE SMA6 reports
    $450K reported (all issues)
  11. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA6 reports
    $50.1M reported (all issues)
  12. RARE DISEASE COMPANY COALITION6 reports
    $460K reported (all issues)
  13. ASSOCIATION FOR CLINICAL ONCOLOGY5 reports
    $1.3M reported (all issues)
  14. AstraZeneca Pharmaceuticals LP5 reports
    $7.4M reported (all issues)Federal contractor: ASTRAZENECA PHARMACEUTICALS LP$500 in contracts, FY2026AI match · 100%
  15. BRIDGEBIO PHARMA INC.5 reports
    $1.6M reported (all issues)
  16. Bayer Corporation (consolidated report)5 reports
    $11.2M reported (all issues)
  17. CHIESI USA, INC.5 reports
  18. EVERYLIFE FOUNDATION FOR RARE DISEASES5 reports
    $220K reported (all issues)
  19. Life Sciences Pennsylvania5 reports
    $6,000 reported (all issues)
  20. ULTRAGENYX PHARMACEUTICAL INC.5 reports
  21. American Cancer Society Cancer Action Network, Inc.4 reports
    $9.1M reported (all issues)
  22. Astria Therapeutics, Inc.4 reports
    $160K reported (all issues)
  23. BIOMARIN PHARMACEUTICAL INC.4 reports
    $1.3M reported (all issues)
  24. NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)4 reports
    $6.1M reported (all issues)
  25. NOVARTIS CORPORATION4 reports
    $8M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  26. ORCHARD THERAPEUTICS NORTH AMERICA4 reports
    $1.2M reported (all issues)
  27. SOLENO THERAPEUTICS, INC.4 reports
    $200K reported (all issues)
  28. Aquestive Therapeutics3 reports
    $180K reported (all issues)
  29. Blood Cancer United (FKA The Leukemia & Lymphoma Society)3 reports
    $860K reported (all issues)
  30. Epilepsy Foundation3 reports
    $210K reported (all issues)
  31. GSK (fka GLAXOSMITHKLINE INC.)3 reports
    $3.3M reported (all issues)
  32. HARMONY BIOSCIENCES, LLC3 reports
    $510K reported (all issues)Federal contractor: HARMONY BIOSCIENCES LLC$614.4K in contracts, FY2026AI match · 100%
  33. LUNDBECK LLC3 reports
    $440K reported (all issues)Federal contractor: LUNDBECK LLCAI match · 99%
  34. NATIONWIDE CHILDREN'S HOSPITAL, INC.3 reports
    $350K reported (all issues)
  35. Rafael Holdings, Inc.3 reports
    $72K reported (all issues)
  36. Tourette Association of America3 reports
    $160K reported (all issues)
  37. Fulcrum Therapeutics2 reports
    $90K reported (all issues)
  38. National Taxpayers Union2 reports
    $60K reported (all issues)
  39. Neurelis, Inc.2 reports
    $20K reported (all issues)
  40. Patients Rising Now2 reports
    $20K reported (all issues)

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.